Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Requests to use off-label cancer treatments handled differently by different trusts

Requests to use treatments off-label for rarer cancers are handled differently by different NHS organisations, according to a report from the Rarer Cancers Forum.

The authors of the report, entitled “Off limits — an investigation into NHS organisations’ policies and processes for determining requests for the use of off-label treatments for people with cancer” (PDF 630K), questioned NHS organisations under the Freedom of Information Act.

They claim that nearly one third of hospital trusts responding to the audit did not have a protocol in place to ensure high-quality clinical governance for off-label treatments. Some trusts said they actively discourage the practice of off-label prescribing: three primary care trusts reported that they have a policy of not funding off-label treatment requests, something the authors of the report suggest could be in breach of the NHS Act. Other trusts acknowledged the need for off-label prescribing.

Extrapolating data reported by 43 primary care trusts, the authors predict that there were over 3,000 requests for off-label treatment in England over the past three years, with just over 1,000 being rejected. Funding the rejected requests would have cost £21.9m, the authors say.

According to the report, the five most commonly requested off-label treatments for cancer are rituximab, sunitinib, lenalidomide, bortezomib and bevacizumab.

The report’s authors make a number of recommendations, including that all NHS trusts develop a protocol or policy for off-label prescribing. They also suggest that the Department of Health should make the production of information for patients on the use of off-label treatments a priority and recommend that the DoH, the Medicines and Healthcare products Regulatory Agency and the Association of the British Pharmaceutical Industry work together to produce guidance clarifying the circumstances under which pharmaceutical companies can provide information on the off-label use of their products to clinicians, charities and policy-makers.

Commenting on the report, David Thomson, chairman of the British Oncology Pharmacy Association and lead pharmacist at the Yorkshire cancer network, told The Journal that the authors do not clearly separate decisions about the use of non-expensive drugs that have been used for a number of years and decisions about new biotech off-label use where there is limited evidence and safety.

Mr Thomson also questioned the motives behind the report, which was funded by a number of pharmaceutical companies. He pointed out that pharmaceutical companies are not allowed to promote the use of off-label medicines.

Citation: The Pharmaceutical Journal URI: 10975985

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.